ABSTRACT: Introduction: Tests of ambulatory function are common clinical trial endpoints in Duchenne muscular dystrophy (DMD). Using these tests, the ImagingDMD study has generated a large data set that can describe the contemporary natural history of DMD in 5-12.9-year-olds. Methods: Ninety-two corticosteroid-treated boys with DMD and 45 controls participated in this longitudinal study. Participants performed the 6-minute walk test (6MWT) and timed function tests (TFT: 10-m walk/run, climbing 4 stairs, supine to stand). Results: Boys with DMD had impaired functional performance even at 5-6.9 years old. Boys older than 7 had significant declines in function over 1 year for 10-m walk/run and 6MWT. Eighty percent of participants could perform all functional tests at 9 years old. TFTs appear to be slightly more responsive and predictive of disease progression than the 6MWT in 7-12.9 year olds. Discussion: This study provides insight into the contemporary natural history of key functional endpoints in DMD.
linked recessive disorder that causes progressive loss of muscle strength leading to significant functional impairment and loss of ambulation in the second decade of life. 1, 2 Glucocorticosteroids are the most frequently used treatment option to modify disease course and delay loss of ambulation by up to 3 years 3 in boys with DMD. Hence, management of DMD largely targets the maintenance of quality of life and function. 4, 5 Even though there is currently no cure for DMD, there is a surge in promising therapeutic strategies that are rapidly moving into and beyond clinical trials. 6, 7 The design of clinical trials has, however, proved challenging, with narrow age and functional inclusion criteria. In addition, limited natural history studies [8] [9] [10] [11] are available in large patient cohorts characterizing disease progression and permitting a comparison with experimental treatment groups. The heterogeneity of disease progression, lack of prior natural history data, and lack of reliable and sensitive clinical endpoints that adequately span a large age range and ambulatory spectrum of the disease have created significant challenges for the design of clinical trials in DMD.
The primary objective of this study was to collect natural history data in a large cohort of ambulatory boys with DMD across multiple centers and to examine 1-year longitudinal changes in performance on the functional tests commonly used as endpoints in clinical trials. A secondary objective was to evaluate the ability of each functional test to predict loss of function in the following year and to examine the relationship between baseline 6-minute walk test (6MWT) performance and functional decline.
MATERIALS AND METHODS
Study Design. The study was approved by the institutional review boards at the University of Florida, Children's Hospital of Philadelphia, and Oregon Health and Science University. Written informed consent and assent were obtained from parents and/or guardians and participants. The participants were enrolled in a longitudinal multicenter MRI natural history study, ImagingDMD (NCT01484678). All participants in the DMD cohort had a genetic diagnosis of DMD as well as onset of symptoms prior to 5 years of age. Additional inclusion and exclusion criteria are provided in the Supporting Information. Here we present data from a subgroup of participants, specifically corticosteroidtreated boys with DMD aged 5-12.9 years and age-matched unaffected controls.
Functional Measures. At each visit, functional test performance was assessed after MRI scans (data not presented). Functional evaluators at each site (n 5 1-3 per site) were trained to perform assessments according to established manuals of operating procedures (MOP). To be certified, all evaluators submitted videos of themselves performing all tests that were evaluated against a standardized evaluation checklist by an expert physical therapist at the central site. After certification, functional evaluators participated in periodic teleconferences as well as annual meetings during which testing procedures were reiterated and MOPs were updated if required.
All tests were performed without the parent or guardian present, and comfortable walking shoes were worn by participants for all tests. The functional evaluator provided verbal encouragement during each test. The order of test performance and the instructions that were given to the participant prior to each test were standardized. Participants first performed timed function tests (TFT): 10-m walk/run, then climbing 4 stairs, then supine to stand (STS). Each timed function test was performed 3 times, and the fastest time was used for analysis. A maximum time of 45 s was provided to complete each test. After TFT testing, participants rested for at least 5 min and then performed the 6MWT as described by McDonald et al. 12 Full details of the instructions for each test can be found in the Supporting Information.
Clinical function was assessed by using the modified Brooke lower extremity scale, 13 and the ability to complete each test was assessed at each visit. Loss of function for the TFTs was defined as inability to complete the test independently within 45 s, and loss of function for the 6MWT was defined as inability to attempt the test or inability to walk without support from a person or wall.
A web interface was used to input data to a secure server during or immediately after functional testing; periodically, all functional test data were inspected by 2 independent reviewers who examined comments entered by the functional evaluator as well as the time or distance recorded and assigned each data set a label of valid or invalid. 14, 15 Annual changes in TFT time or 6MWD were compared with thresholds for clinically important decline as defined by McDonald et al. 16 Annual changes in TFT velocity and 6MWD were also used to calculate the standardized response mean (SRM, mean change/standard deviation of the change). Sample sizes for a hypothetical clinical trial of a treatment that either completely stabilized the disease or slowed disease progression by 50% were calculated from the change over 12 months in 7-12.9-year-old boys with the same methods used by Bonati et al.
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By using all available data for each boy with DMD (n 5 288 visits), receiver operating characteristic curves (ROC) were estimated to investigate loss of function. Sensitivity and specificity are reported at the point on the ROC closest to (0, 100%). To properly account for uncertainty in this analysis, given multiple (correlated) time points from the same participant, we used the bootstrap (resampling participants, not individual data points for a participant) to compute 95% confidence intervals for the area under the curve (AUC), the optimal cutoff, and the sensitivity and specificity.
RESULTS
Demographic Information. Demographic data for affected and unaffected boys at baseline are provided in Table  T1 1. Eighty boys with DMD completed a follow-up visit 12.1 6 0.5 months after baseline, and additional follow up visits were completed by 74 boys at 2 years, 36 boys at 3 years, 36 boys at 4 years after baseline. Genetically, 67% of boys had deletion mutations, 10% had duplication mutations, and 21% had point mutation/others; 2% had a genetic diagnosis of DMD per parent report, but a genetic report was not available. Control participants did not differ in age from boys with DMD (Table 1) . Across all tests completed, 98% yielded valid data; 2% were invalid due to compliance or behavioral issues and were not included in analysis. In addition, 0.5% of tests had missing data, typically because a participant or parent did not agree to participate in that test.
Baseline Functional Performance. At baseline, controls performed TFTs significantly more quickly compared with boys with DMD and walked significantly farther on the 6MWT (Table  T2 2, Supp. Info. Fig.  F1 1). The magnitude of this difference increased with age. The youngest boys took about twice as long as controls to complete the TFTs, and the older boys took 3-4 times longer. At younger ages, boys with DMD walked about 75% of the distance measured in controls, whereas older boys with DMD walked just over 50% of the distance of their peers. This was true for raw 6MWD as well as percentage predicted 6MWD, which takes into account stature and age. The distribution of baseline TFT values in boys with DMD is illustrated in Supporting Information Figure 2 . The 6MWT and 10-m walk/run test both measure ambulatory function and, as expected, were significantly correlated with each other (Supp. Info. Fig. 3 ). However, in highly functional boys, the relationship between the 2 tests is less strong than in boys whose performance is declining.
Functional Changes Over 1 Year. Performance on all functional tests as well as percentage predicted 6MWD significantly declined over 12 months in boys with DMD aged 7-10 years ( Table 2 , Fig. 1 ). Significant declines in 10-m walk/run and 6MWT performance but not climbing 4 stairs or STS were seen in 11-12.9 year-old-boys. In boys < 7 years, no FIGURE 1. Decline in 6MWT performance over 1 year across ages. A significant decline in 6MWT over 1 year was found for boys >7 years of age for both (a) 6MWT and (b) percentage predicted 6MWT. P < 0.05. 6MWT, 6-minute walk test. Although most of the youngest boys were able to complete the TFTs in <5 s at baseline and 1 FIGURE 2. Change over 1 year for all functional tests for all age groups in boys with DMD. Overall there was a shift to slower times/ shorter distance in boys aged >7 years but not in younger boys. Data represent 19 boys aged 5-6.9, 23 boys 7-8.9, 22 boys 9-10.9, and 16 boys 11-12.9 years. Missing data or invalid data did not exceed 10% for any test in any age group. 6MWT, 6-minute walk test; BL, baseline; DMD, Duchene muscular dystrophy; STS, supine to stand. year follow-up, by 9-10 years of age a number of boys could no longer complete these tests in less than 10 s (Fig.  F2 2). When boys were grouped by baseline 6MWD instead of by baseline age (Fig.  F3 3), boys with baseline 6MWD < 300 m were very likely to experience clinically important declines in performance on all functional outcomes over 12 months. Boys with 6MWD 376 m were highly likely to remain stable, as measured by the TFTs and the 6MWT over 12 months. A subset of boys in all baseline 6MWD groups experienced clinically important improvements in 6MWD, but no participants showed clinically important improvement over 12 months in the TFTs. This was also true when boys walking <350 m and 350 m, a cut-off threshold that has been used in the past, were compared 8, 11 (Sup. Info Fig. 4) .
Loss of Function. Figure  F4 4 displays the longitudinal trajectory in 6MWD performance as a function of age and baseline 6MWD across all available visits. No participant with baseline 6MWD 451 m lost ambulation over the course of 4 years, whereas a substantial proportion of boys with baseline 6MWD < 376 m had lost ambulation at the 2-year follow-up visit. Eighty percent of boys with DMD maintained the ability to complete all functional tests until 9 years of age (Fig.  F5  5) . However, after 12 years, functional decline was rapid, and by 14 years, only half of participants could still complete the 6MWT or 10-m walk/run. ROC analysis was used to examine the predictive relationship between functional performance and loss of function (Table  T3 3) and showed that all tests were significantly predictive of loss of function, with slightly higher AUC for the TFTs compared with the 6MWD. The cutoff value that best predicted loss of function was between 6 and 7.5 s for each of the TFTs, and the cutoff value that best predicted loss of function for the 6MWT was 319 m.
DISCUSSION
Boys with DMD had impaired functional performance on tests of ambulatory function commonly used as clinical trial endpoints even at 5-6.9 years of age; however, only boys 7 years or older showed significant declines in functional test performance over 1 year for 10-m walk/run and 6MWT tests. Eighty percent of enrolled participants remained able to complete all 4 functional tests until at least 9 years old, and, by age 14, approximately 50% of the boys could still complete the 6MWT or the 10-m walk/run. All functional tests were able to predict the loss of function over 12 months, with the TFTs displaying slightly higher sensitivity and responsiveness to change than the 6MWD. Finally, classification of the participants based on baseline 6MWD showed that boys with 6MWD 300 m were very likely to experience clinically important declines in performance on all the functional tests over 12 months, and boys with 6MWD 376 m were highly likely to remain stable. The cohort of participants described in this article is broadly similar in baseline 6MWD performance to other large natural history cohorts, 8, 18 despite differences in standard of care and functional inclusion criteria. The average decline in 6MWD over the course of 1 year (21 m) was smaller than the 44-m decline measured over 48 weeks in the placebo-treated group of the ataluren clinical trial. 8 Unlike previous studies, the current study also included an unaffected age-matched cohort, allowing us to quantify the increasing gap in performance between boys with DMD and their peers with age. All controls completed the 10-m walk/run test in 3 s and the STS and climbing 4 stairs in 1-2 s. These normative data may be helpful in understanding alterations in disease progression with treatment in DMD.
The choice of primary endpoint for a clinical trial is critical to the success of the trial. An ideal primary endpoint is highly sensitive to disease progression, and, conversely, a treatment-related slowing of the disease and can be measured in all participants for the duration of the study. A number of trials have used the 6MWT as a primary endpoint; however, the 6MWT has recently come under some criticism. 19, 20 TFTs, including the 10-m walk/run, climbing 4 stairs, and STS, offer potentially appealing alternative primary endpoints for use in ambulatory patients.
In this ImagingDMD cohort of ambulatory patients uniformly treated with corticosteroids, the responsiveness of all tests was low in 5-6.9-year-old boys with DMD, requiring the development of other outcome measures. This is consistent with the known stability or even gains in motor skills observed in boys with DMD at younger ages, followed by a progressive decline. The slightly lower responsiveness of the 6MWT compared with the TFTs may have important implications for the number of participants required to detect a treatment-related stabilization in clinical trials. We estimate that, were the 6MWT used as the primary outcome, a trial would require 50 boys to detect a complete stabilization in the treated cohort over 1 year or 256 boys to detect a 50% slowing of disease progression. On the other hand, if the trial used the 10-m walk/run, we estimate that 17 boys would be required to detect complete stabilization, and 68 boys would be required to detect a 50% slowing of disease progression.
It is important to regulatory authorities that the chosen primary endpoint is related to clinically meaningful disease events. In DMD, loss of the ability to get up from the floor, climb stairs, or walk are important milestones to the patient. Loss of each of these abilities can be predicted from the respective test. In this study, we observed that the TFTs were slightly stronger than the 6MWT as predictors of loss of function. This is important information in planning a clinical trial; each participant who loses the ability to complete a test compromises the statistical power and, thus, the ability to detect a treatment effect. The results of ROC analysis suggest that boys who take less than 6 to 7.5 s to complete the TFTs or walk more than 319 m on the 6MWT are more likely to retain the ability to complete that test over 12 months. The 10-m walk/run threshold estimated here, 7.5 s, is substantially lower than the 10-s threshold previously reported. 8 On the other hand, the 6MWT threshold is similar to previous reports. 8, 11 Age is another important predictor of loss of function, and this study found that, at 9 years of age, > 80% of corticosteroid-treated boys could still complete all tests. However, by 14 years, about half of the boys were unable to complete any of the tests.
Inclusion criteria for a study may target a population in which it is possible to observe differences in the decline in function. 21 The 6MWT has previously shown promise in predicting decline. 8 In the current study, 6MWD was effective in predicting functional stability or decline in performance on the TFTs, with boys walking 376 m likely to remain stable. The relationship between baseline 6MWD and future change in the 6MWT itself was limited. Maturational improvements in 6MWD in younger boys may make future changes in 6MWD more difficult to predict in a diverse sample.
This large multicenter natural history study provides important information to help guide clinical trial design in that the 10-m walk/run may be slightly more sensitive than the 6MWT in 7-12.9-year-old corticosteroid-treated boys. We conjecture that the 6MWT may be less sensitive to changes in muscle performance per se because it does not measure muscle power but rather is reflective of cardiopulmonary function and potentially overall "well being." In keeping with this, we found that, although the overall relationship between the 6MWT and the 10-m walk/run was strong, the relationship was less pronounced in highly functional boys, who are most likely to be running during the 10-m walk/run. Given the duration of the test, performance on the 6MWT may also be more subject to compensatory strategies and influenced by motivation. 22 We propose that the 10-m walk/run test offers a valuable alternative, providing high sensitivity, a strong predictive value, and the ability to be performed in a large proportion of the boys (>80%) until the age of 12 years. In contrast, the STS and climbing 4 stairs tests both have good sensitivity to change in 7-10 year-old-boys with DMD but do not detect functional progression in older boys, a high proportion of whom have lost the ability to perform these tests. In addition, the climbing 4 stairs time is susceptible to commonly used compensatory movement strategies, such as leaning on the handrail, to complete the task, reducing its specificity to ambulatory decline.
This study included only corticosteroid-treated participants. Current clinical trials typically specify corticosteroid status as an inclusion criterion, selecting only treated or untreated boys. In contrast, most large natural history studies to date have included both steroid-treated and untreated boys, limiting the applicability of their results to clinical trial planning. Although the ImagingDMD study includes both steroid-treated and untreated participants, the volume of data in steroiduntreated boys is too limited to include in the current article; a set of these results was published previously. 23 There are some limitations to this study. We did not account for the presence or impact of differences in clinical care, such as age at steroid initiation, use of dietary supplements and medications, or physical therapy treatment. The impact of primary genetic mutation was not examined. Assessments in this study took place annually, and no information is available about the timing of changes in function, such as loss of ambulation, between visits. Finally, the inclusion criteria in this study targeted participants who were able to walk >100 m and climb 4 stairs at baseline, whereas other natural history studies and clinical trials may have used other thresholds for inclusion. [8] [9] [10] [11] In conclusion, the results of this study provide compelling evidence supporting the use of TFTs as primary outcomes in clinical trials, particularly the 10-m walk/run, which may be especially valuable given potential limitations of the 6MWT. 19, 20 In addition, we believe that this study offers critical contemporary natural history data in corticosteroid-treated boys with DMD as well as normative control data that are of value to many in the DMD community.
